The TRIPS Agreement and

A further problem is that new artemisinin-based treatments continue to be as much as twenty times more expensive than chloroquine. Though outdated, this means many African countries continue to rely on chloroquine for their treatment programs. New drugs and an effective vaccine are in high need yet R&D continues to be insufficient. ................
................